Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | RAC1 | P63000 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444093 | 0.84 | CES2 (0.47) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL6474804 | 0.84 | CES2 (0.47) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL27804095 | 0.82 | PTGS2 (0.49) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL10764332 | 0.82 | CES2 (0.45) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL28657119 | 0.81 | CA1 (0.47) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL38664793 | 0.81 | CYP1A2 (0.49) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL14648180 | 0.79 | MAPT (0.53) | CA1CA2ACP3L3MBTL1LDHA | |
| SCHEMBL10608029 | 0.78 | TGM2 (0.47) | CA1CA2ACP3L3MBTL1CES2 | |
| SCHEMBL14648184 | 0.78 | MAPT (0.52) | ACP3L3MBTL1CES2CES1RAB9A | |
| SCHEMBL13427773 | 0.77 | GAA (0.50) | NPSR1MEN1KMT2ACYP1A2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-6867297-B1 | Process for synthesizing 4-substituted azetidinone derivatives | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-0638552-B1 | PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6051569-A | 1'S, 5R, 6R-carbapenem derivatives and antimicrobial agents comprising the same | SUNTORY LIMITED (JP) | 2000-04-18 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0826687-A1 | Carbapenem derivatives and antimicrobial agents comprising the same | SUNTORY LIMITED (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0774465-A1 | Penem derivatives and antimicrobial agents containing the same | SUNTORY LIMITED (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0638552-A1 | PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CA1 23/4885CA2 608/4885ACP3 387/4885 |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | CA1 4842/4885CA2 4652/4885ACP3 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.